Pharma Announces Positive Results of Two Pivotal Phase-3 Clinical Trials of Tildrakizumab

In patients with moderate-to-severe plaque psoriasis

Sun Pharma announced that two pivotal Phase-3 clinical trials evaluating the efficacy and safety of the investigational IL-23p19 inhibitor antibody tildrakizumab (MK-3222) in patients with moderate-to-severe plaque psoriasis met their primary endpoints for both evaluated doses.

Powered by Capital Market - Live News